PMID- 15145115
OWN - NLM
STAT- MEDLINE
DCOM- 20040629
LR  - 20151119
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 43
IP  - 10
DP  - 2004 May 19
TI  - Urinary biopyrrins levels are elevated in relation to severity of heart failure.
PG  - 1880-5
AB  - OBJECTIVES: We investigated the relationship between the urinary levels of 
      biopyrrins and the severity of heart failure (HF). BACKGROUND: Oxidative stress 
      is evident in heart disease and contributes to the development of ventricular 
      dysfunction in patients with HF. Biopyrrins, oxidative metabolites of bilirubin, 
      have been discovered as potential markers of oxidative stress. METHODS: We 
      measured the levels of urinary biopyrrins and plasma B-type natriuretic peptide 
      (BNP) in 94 patients with HF (59 men; mean age 65 years) and 47 control subjects 
      (30 men; mean age 65 years). Urine and blood samples were taken after admission 
      in all subjects. Further urine samples were obtained from 40 patients after 
      treatment of HF. RESULTS: The urinary biopyrrins/creatinine levels (micromol/g 
      creatinine) were the highest in patients in New York Heart Association (NYHA) 
      class III/IV (n = 26; 17.05 [range 7.85 to 42.91]). The urinary 
      biopyrrins/creatinine levels in patients in NYHA class I (n = 35; 3.46 [range 
      2.60 to 5.42]) or II (n = 33; 5.39 [range 3.37 to 9.36]) were significantly 
      higher than those in controls (2.38 [range 1.57 to 3.15]). There were significant 
      differences in urinary biopyrrins/creatinine levels among each group. The 
      treatment of HF significantly decreased both urinary biopyrrins/creatinine levels 
      (from 7.43 [range 3.84 to 17.05] to 3.07 [range 2.21 to 5.71]) and NYHA class 
      (from 2.5 +/- 0.1 to 1.7 +/- 0.1). Log biopyrrins/creatinine levels were 
      positively correlated with log BNP levels (r = 0.650, p < 0.001). CONCLUSIONS: 
      These results indicate that urinary biopyrrins levels are increased in patients 
      with HF and are elevated in proportion to its severity.
FAU - Hokamaki, Jun
AU  - Hokamaki J
AD  - Department of Cardiovascular Medicine, Kumamoto University School of Medicine, 
      Kumamoto, Japan.
FAU - Kawano, Hiroaki
AU  - Kawano H
FAU - Yoshimura, Michihiro
AU  - Yoshimura M
FAU - Soejima, Hirofumi
AU  - Soejima H
FAU - Miyamoto, Shinzo
AU  - Miyamoto S
FAU - Kajiwara, Ichiro
AU  - Kajiwara I
FAU - Kojima, Sunao
AU  - Kojima S
FAU - Sakamoto, Tomohiro
AU  - Sakamoto T
FAU - Sugiyama, Seigo
AU  - Sugiyama S
FAU - Hirai, Nobutaka
AU  - Hirai N
FAU - Shimomura, Hideki
AU  - Shimomura H
FAU - Nagayoshi, Yasuhiro
AU  - Nagayoshi Y
FAU - Tsujita, Kenichi
AU  - Tsujita K
FAU - Shioji, Izuru
AU  - Shioji I
FAU - Sasaki, Shinya
AU  - Sasaki S
FAU - Ogawa, Hisao
AU  - Ogawa H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Biomarkers)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - RFM9X3LJ49 (Bilirubin)
SB  - IM
MH  - Aged
MH  - Bilirubin/metabolism
MH  - Biomarkers/blood/urine
MH  - Female
MH  - Heart Failure/blood/complications/*physiopathology/*urine
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood/urine
MH  - Oxidative Stress
MH  - Severity of Illness Index
MH  - Ventricular Dysfunction/blood/etiology/physiopathology/urine
EDAT- 2004/05/18 05:00
MHDA- 2004/06/30 05:00
CRDT- 2004/05/18 05:00
PHST- 2003/08/25 00:00 [received]
PHST- 2003/12/24 00:00 [revised]
PHST- 2004/01/08 00:00 [accepted]
PHST- 2004/05/18 05:00 [pubmed]
PHST- 2004/06/30 05:00 [medline]
PHST- 2004/05/18 05:00 [entrez]
AID - S0735109704004589 [pii]
AID - 10.1016/j.jacc.2004.01.028 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2004 May 19;43(10):1880-5. doi: 10.1016/j.jacc.2004.01.028.